A Relative Bioavailability Study of Gabapentin 800 mg Tablets Under Fasting Conditions
Status:
Completed
Trial end date:
1999-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the relative bioavailability of 800 mg Gabapentin
Tablets by Purepac Pharmaceutical Co. with that of 400 mg (2 x 400 mg) NEURONTIN® by
Parke-Davis under fasting conditions.